Abstract
Hemophiliac patients receiving FC have immunological abnormalities associated with AIDS. Although a high percentage of hemophiliacs have antibody titers to HTLV-III, the etiology of their altered immune status is unclear. We have studied the in vitro effects of FC on mitogenic responses of normal peripheral blood mononuclear cells (PBM). Ten lots of FC (including one heat-treated and two associated with cases of AIDS) from 5 manufacturers were assayed. These were added in physiological concentrations to cultures of PBM stimulated with suboptimal and optimal concentrations of PHA (2 and 50 ug/ml, respectively). Addition of these FC significantly reduced the proliferative response in a dose dependent manner. One U/ml FC resulted in an average suppression of 40% at 2 ug/ml and 34% at 50 ug/ml PHA. At 0.5 U/ml, average suppression was 35% at 2 ug/ml and 18% at 50 ug/ml PHA. Two hour pre-incubation with PHA prior to addition of FC resulted in similar suppression; however, 24 hr preincubation resulted in less suppression. Neither column-purified Factor VIII activity or antigen had significant inhibitory effects. Cell viabilities in FC cultures were similar to control cultures. These results suggest that commericially available FC contains a factor(s) other than HTLV-III which inhibits the proliferative responses of normal lymphocytes. Efforts to isolate this factor(s) are currently in progress.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mann, M., Daul, C., Andes, W. et al. 1005 IN VITRO EFFECTS OF COMMERCIAL FACTOR VIII CONCENTRATES (FC) ON THE FUNCTION OF NORMAL LYMPHOCYTES. Pediatr Res 19, 278 (1985). https://doi.org/10.1203/00006450-198504000-01035
Issue Date:
DOI: https://doi.org/10.1203/00006450-198504000-01035